What Nanotech Means to Health Care Investors
This article was originally published in Start Up
Executive Summary
If there's a common theme being articulated by CEOs of nanobiotechnology start-ups, it's that, at least financially, life has been difficult because they're early stage. Indeed, the nanotech label is less significant to health care investors than considerations related to their business strategy. Drug-delivery-oriented nanobiotechs, for example, must be strongly product focused to avoid the implications that they have an old, low-value model.